Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 57
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Premature Death, Suicide, and Nonlethal Intentional Self-Harm After Psychiatric Discharge

  • Mortier, Philippe|||0000-0003-2113-6241
  • Conde, Susana
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Amigo, Franco|||0000-0002-3602-5168
  • Ballester, Laura
  • Cirici Amell, Roser
  • Guinart, Daniel
  • Contaldo, Salvatore Fabrizio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Leis, Angela
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Portillo-Van Diest, Ana|||0000-0001-7199-8339
  • Puértolas-Gracia, Beatriz
  • Ramírez-Anguita, Juan Manuel|||0000-0002-8509-0927
  • Peña-Salazar, Carlos
  • Sanz, Ferran|||0000-0002-7534-7661
  • Kessler, Ronald|||0000-0003-4831-2305
  • Palao, Diego|||0000-0002-3323-6568
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Mehlum, Lars|||0000-0003-2813-0045
  • Qin, Ping
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Alonso, Jordi|||0000-0001-8627-9636
This cohort study estimates rates of all-cause premature death, suicide, and nonlethal intentional self-harm after discharge from a psychiatric hospitalization among patients in Spain and investigates associations of these outcomes with variables including sex and mental disorders. What is the risk for premature death, suicide, and nonlethal intentional self-harm following discharge from psychiatric hospitalization? In this cohort study including 49 108 patients, risk for postdischarge premature death (age <70 years) and suicide was significantly higher compared with the general population. Premature death was associated with cognitive disorders and alcohol-related disorders in both sexes; suicide was associated with postdischarge nonlethal intentional self-harm in both sexes, with depressive and adjustment disorders in males, and with bipolar disorder in females. The findings suggest individuals discharged from psychiatric inpatient care constitute a vulnerable population for premature death and suicidal behavior. There is a need for representative research on serious adverse outcomes following discharge from psychiatric hospitalization. To compare rates of premature death, suicide, and nonlethal intentional self-harm after psychiatric discharge with rates in the general population and investigate associations of these outcomes with relevant variables associated with the index psychiatric hospitalization. This retrospective cohort study included all residents from Catalonia, Spain (7.6 million population), who had psychiatric hospitalizations between January 1, 2014, and December 31, 2018, and were older than 10 years at the index (first) hospitalization. Follow-up was until December 31, 2019. Statistical analysis was performed from December 1, 2022, through April 11, 2024. Socioeconomic status, psychiatric diagnoses, duration of index hospitalization, and number of previous psychiatric hospitalizations. Postdischarge premature death (ie, all-cause death before age 70 years) and suicide (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code range X60-X84), identified using mortality data, and postdischarge nonlethal intentional self-harm, identified using electronic health record and self-harm case register data. Standardized mortality ratios (SMRs) compared rates of premature death and suicide between the cohort and the general population. Fully adjusted, multivariable, cause-specific Cox proportional hazards regression models for the 3 outcomes were fitted. A total of 49 108 patients discharged from psychiatric hospitalization were included (25 833 males [52.6%]; mean [SD] age at discharge, 44.2 [18.2] years). During follow-up, 2260 patients (4.6%) died prematurely, 437 (0.9%) died by suicide, and 4752 (9.7%) had an episode of nonlethal intentional self-harm. The overall SMR for premature death was 7.5 (95% CI, 7.2-7.9). For suicide, SMR was 32.9 (95% CI, 29.9-36.0) overall and was especially high among females (47.6 [95% CI, 40.2-54.9]). In fully adjusted sex-stratified hazard models, postdischarge premature death was associated with cognitive disorders (adjusted hazard ratio [AHR], 2.89 [95% CI, 2.24-3.74] for females; 2.59 [95% CI, 2.17-3.08] for males) and alcohol-related disorders (AHR, 1.41 [95% CI, 1.18-1.70] for females; 1.22 [95% CI, 1.09-1.37] for males). Postdischarge suicide was associated with postdischarge intentional self-harm (AHR, 2.83 [95% CI, 1.97-4.05] for females; 3.29 [95% CI, 2.47-4.40] for males), with depressive disorders (AHR, 2.13 [95% CI, 1.52-2.97]) and adjustment disorders (AHR, 1.94 [95% CI, 1.32-2.83]) among males, and with bipolar disorder among females (AHR, 1.94 [95% CI, 1.21-3.09]). Postdischarge intentional self-harm was associated with index admissions for intentional self-harm (AHR, 1.95 [95% CI, 1.73-2.21] for females; 2.62 [95% CI, 2.20-3.13] for males) as well as for adjustment disorders (AHR, 1.48 [95% CI, 1.33-1.65] for females; 1.99 [95% CI, 1.74-2.27] for males), anxiety disorders (AHR, 1.24 [95% CI, 1.10-1.39] for females; 1.36 [95% CI, 1.18-1.58] for males), depressive disorders (AHR, 1.54 [95% CI, 1.40-1.69] for females; 1.80 [95% CI, 1.58-2.04] for males), and personality disorders (AHR, 1.59 [95% CI, 1.46-1.73] for females; 1.43 [95% CI, 1.28-1.60] for males). In this cohort study of patients discharged from psychiatric hospitalization, risk for premature death and suicide was significantly higher compared with the general population, suggesting individuals discharged from psychiatric inpatient care are a vulnerable population for premature death and suicidal behavior.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ABCDE to identify and prevent chronic kidney disease, a call to action

  • Ferro, Charles|||0000-0003-0577-7081
  • Wanner, Christoph|||0000-0001-9507-5301
  • Luyckx, Valerie|||0000-0001-7066-8135
  • Stevens, Kate|||0000-0003-2291-1692
  • Cerqueira, Sofia
  • Darwish, Rasha
  • Fernandez, Beatriz Fernandez
  • Fiel, David
  • Filev, Rumen
  • Grieger, Manfred
  • Lopez, Antonia
  • Luman, Merike
  • Malyszko, Jolanta
  • Nikolova-Vlahova, Milena Krasimirova
  • Romero, Fiita
  • Skalioti, Chrysanthi
  • Ribeiro dos Santos Araújo, Carla Alexandra
  • Ziedina, Ieva
  • Gallego, Daniel
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Vanholder, Raymond|||0000-0003-2633-1636
Kidney disease is a global health priority affecting.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Rossell, Joana|||0000-0003-1500-6379
  • Alonso, N.
  • Weber, R.J.M.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Lloyd, G.R.
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Winder, Catherine|||0000-0002-1648-5255
  • Junza, Alexandra
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: Disruption of lipid metabolism contributes to increased cardiovascular risk in diabetes. Methods: We evaluated the associations between serum lipidomic profile and subclinical carotid atherosclerosis (SCA) in type 1 (T1D) and type 2 (T2D) diabetes, and in subjects without diabetes (controls) in a cross-sectional study. All subjects underwent a lipidomic analysis using ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry, carotid ultrasound (mode B) to assess SCA, and clinical assessment. Multiple linear regression models were used to assess the association between features and the presence and burden of SCA in subjects with T1D, T2D, and controls separately. Additionally, multiple linear regression models with interaction terms were employed to determine features significantly associated with SCA within risk groups, including smoking habit, hypertension, dyslipidaemia, antiplatelet use and sex. Depending on the population under study, different confounding factors were considered and adjusted for, including sample origin, sex, age, hypertension, dyslipidaemia, body mass index, waist circumference, glycated haemoglobin, glucose levels, smoking habit, diabetes duration, antiplatelet use, and alanine aminotransferase levels. Results: A total of 513 subjects (151 T1D, 155 T2D, and 207 non-diabetic control) were included, in whom the percentage with SCA was 48.3%, 49.7%, and 46.9%, respectively. A total of 27 unique lipid species were associated with SCA in subjects with T2D, in former/current smokers with T2D, and in individuals with T2D without dyslipidaemia. Phosphatidylcholines and diacylglycerols were the main SCA-associated lipidic classes. Ten different species of phosphatidylcholines were up-regulated, while 4 phosphatidylcholines containing polyunsaturated fatty acids were down-regulated. One diacylglycerol was down-regulated, while the other 3 were positively associated with SCA in individuals with T2D without dyslipidaemia. We discovered several features significantly associated with SCA in individuals with T1D, but only one sterol could be partially annotated. Conclusions: We revealed a significant disruption of lipid metabolism associated with SCA in subjects with T2D, and a larger SCA-associated disruption in former/current smokers with T2D and individuals with T2D who do not undergo lipid-lowering treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data

  • Manzini, E.|||0000-0003-2961-5335
  • Vlacho, Bogdan|||0000-0003-3768-8112
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Escudero, J.
  • Génova, A.
  • Reixach, Elisenda|||0000-0001-8557-0771
  • Andrés, E.
  • Pizarro, I.
  • Mauricio, Didac|||0000-0002-2868-0250
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
Recent evidence indicates that Type 2 Diabetes Mellitus (T2DM) is a complex and highly heterogeneous disease involving various pathophysiological and genetic pathways, which presents clinicians with challenges in disease management. While deep learning models have made significant progress in helping practitioners manage T2DM treatments, several important limitations persist. In this paper we propose DARE, a model based on the transformer encoder, designed for analyzing longitudinal heterogeneous diabetes data. The model can be easily fine-tuned for various clinical prediction tasks, enabling a computational approach to assist clinicians in the management of the disease. We trained DARE using data from over 200,000 diabetic subjects from the primary healthcare SIDIAP database, which includes diagnosis and drug codes, along with various clinical and analytical measurements. After an unsupervised pre-training phase, we fine-tuned the model for predicting three specific clinical outcomes: i) occurrence of comorbidity, ii) achievement of target glycemic control (defined as glycated hemoglobin <7%) and iii) changes in glucose-lowering treatment. In cross-validation, the embedding vectors generated by DARE outperformed those from baseline models (comorbidities prediction task AUC=0.88, treatment prediction task AUC=0.91, HbA1c target prediction task AUC=0.82). Our findings suggest that attention-based encoders improve results with respect to different deep learning and classical baseline models when used to predict different clinical relevant outcomes from T2DM longitudinal data.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteostasis disruption and lipid dyshomeostasis in neurodegeneration, exploring common druggable targets across sporadic and monogenic disorders

  • Pereira Sena, Priscila
  • Friedrich, Lea
  • Villarreal, Alcibiades
  • Fath, Florian
  • Sopco, Liubovi
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Saraiva-Pereira, Maria Luiza
  • Britton, Gabrielle
  • Weber, Jonasz Jeremiasz
  • Schmidt, Thorsten
Neurodegenerative disorders pose an increasing burden in the aging society. These conditions share several molecular pathomechanisms, some of which may offer opportunities for therapeutic intervention. In this review, we explore a representative selection of sporadic and hereditary neurodegenerative diseases-namely Alzheimer's disease, cerebral amyloid angiopathy, and the polyQ disorders spinocerebellar ataxia types 2 and 3, as well as Huntington's disease-which all feature the accumulation of intra- or extracellular protein deposits as a hallmark. We place particular emphasis on dysregulations in proteostasis-underlying the formation of these aggregates-and the less commonly addressed disturbances in lipid metabolism. By highlighting potential mechanistic links across different classes of neurodegenerative diseases, we aim to provide new insights that may guide the identification of shared druggable targets and the development of broad-spectrum therapeutic strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Maintaining kidney health in aging societies, a JSN and ERA call to action

  • Ortiz, Alberto|||0000-0002-9805-9523
  • Kramer, A.|||0000-0002-7560-2669
  • Rychlík, Ivan|||0000-0002-4245-5949
  • Nangaku, Masaomi|||0000-0001-7401-2934
  • Yanagita, Motoko|||0000-0002-0339-9008
  • Jager, Kitty|||0000-0003-0444-8569
  • Caskey, Fergus
  • Stel, Vianda S.
  • Kuragano, Takahiro|||0000-0001-6453-3824
  • Yokoi, Hideki|||0000-0001-8343-9737
  • Fliser, Danilo
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Wanner, Christoph|||0000-0001-9507-5301
  • Kashihara, Naoki
  • Suzuki, Yusuke
  • Takemoto, Yoshiaki
  • Palladino, Giuseppe
Chronic kidney disease (CKD) is the fastest growing cause of death, expected to become the fifth global cause of death and the third in some countries with long life expectancy, such as Japan and Spain, by 2050. This reflects societal aging, as advancing kidney age is the main risk factor for CKD. The forecasted 140% increase in the death rate from CKD by 2050 is reduced to 33% when adjusted for age. The increasing mortality burden is paralleled by higher personal, healthcare, socio-economic and environmental burdens and the need for kidney replacement therapy to treat kidney failure. To some extent, the higher CKD burden represents the price of success in prolonging longevity by decreasing other causes of death. Now is the time to act to minimize the negative impact of CKD on aging societies through primary prevention and early diagnosis and treatment of CKD. Action aimed at maintaining kidney health and delaying biological kidney aging will contribute to healthy aging, as the kidneys have gerosuppressor functions and CKD has the highest negative impact on body aging among chronic non-communicable diseases. This action should be part of a move towards novel holistic approaches to healthy longevity represented by concepts such as cardiovascular-kidney-metabolic health, geromedicine, gerosuppressors and organ rejuvenation. We discuss a conceptual framework for the present and future of kidney aging and kidney health in the elderly, emphasizing opportunities for intervention that underlie the Japanese Society of Nephrology and European Renal Association call to action on Achieving Kidney Health in Aging/Aged Societies.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

MOSim: bulk and single-cell multilayer regulatory network simulator

  • Monzó, Carolina
  • Martínez-Mira, Carlos
  • Arzalluz-Luque, Ángeles
  • Conesa, Ana
  • Aguerralde-Martin, Maider|||0000-0001-9266-8689
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] As multi-omics sequencing technologies advance, the need for simulation tools capable of generating realistic and diverse (bulk and single-cell) multi-omics datasets for method testing and benchmarking becomes increasingly important. We present MOSim, an R package that simulates both bulk (via mosim function) and single-cell (via sc_mosim function) multi-omics data. The mosim function generates bulk transcriptomics data (RNA-seq) and additional regulatory omics layers (ATAC-seq, miRNA-seq, ChIP-seq, Methyl-seq, and transcription factors), while sc_mosim simulates single-cell transcriptomics data (scRNA-seq) with scATAC-seq and transcription factors as regulatory layers. The tool supports various experimental designs, including simulation of gene co-expression patterns, biological replicates, and differential expression between conditions. MOSim enables users to generate quantification matrices for each simulated omics data type, capturing the heterogeneity and complexity of bulk and single-cell multi-omics datasets. Furthermore, MOSim provides differentially abundant features within each omics layer and elucidates the active regulatory relationships between regulatory omics and gene expression data at both bulk and single-cell levels. By leveraging MOSim, researchers will be able to generate realistic and customizable bulk and single-cell multi-omics datasets to benchmark and validate analytical methods specifically designed for the integrative analysis of diverse regulatory omics data., This work was supported by the Scientific Foundation of the Spanish Association Against Cancer through the project PERME224336TARA and by Instituto de Salud Carlos III through the project AC22/00058 (co-funded by the European Union as part of the Next Generation EU programme and the Recovery and Resilience Mechanism, MRR), both projects under the frame of ERA PerMed (ERAPERMED2022-141 OVA-PDM). This work also received funding from the FP7 STATegra project (agreement no. 306000), the Spanish MINECO (BIO2012-40244), the Spanish MICIN (PID2020-119537RB-100), the Spanish Bioinformatics Institute support (PT17/0009/0015-ISCIII-SGEFI/ERDF), the Scientific Foundation of the Spanish Association Against Cancer (PERME224336TARA), under the frame of ERA PerMed (ERAPERMED2022-141 OVA-PDM), and the European Union's programme Horizon Europe under a Marie Sk&#322;odowska-Curie grant (101149931).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

MOREshiny: a user-friendly application for the inference of phenotype-specific multi-omic regulatory networks

  • Aguerralde-Martin, Maider|||0000-0001-9266-8689
  • Tarazona, Sonia|||0000-0001-5346-1407
  • Moldovan-Moldovan, Roxana Andreea
  • Verdú, María
[EN] Deciphering phenotype-specific regulatory mechanisms is key to understanding the molecular basis of complex diseases and traits. However, constructing multi-omic regulatory networks (MO-RNs) is challenging, as it requires integrating heterogeneous omics data, incorporating biological context, and detecting regulatory mechanisms that vary across conditions. The R package MORE (Multi-Omics REgulation) addresses these challenges by applying robust statistical models to infer phenotype-specific regulatory networks from multi-omics data. However, the use of MORE typically requires programming expertise, limiting its accessibility to non-specialist users. To democratize access to advanced multi-omics modeling tools, we present MOREshiny, an interactive web application built on Shiny that extends the module of pathway enrichment analysis and automatically guides the choice of statistical methods. MOREshiny enables users to upload multi-omic data, configure their models, and interpret results through a user-friendly interface-without the need for coding skills. MOREshiny also allows users to download MORE results for their later exploration and study. To demonstrate the utility of MOREshiny, we showcase its functionalities on a multi-omic ovarian cancer dataset to understand regulatory differences between patients who did or did not require chemotherapy., This work was supported by the Scientific Foundation of the Spanish Association Against Cancer [PERME224336TARA] and the Instituto de Salud Carlos III [AC22/00058] (co-funded by the European Union as part of the Next Generation EU programme and the Recovery and Resilience Mechanism, MRR), both under the frame of ERA PerMed [ERAPERMED2022-141 OVA-PDM]; and the Spanish Ministry of Science, Innovation and Universities [PID2023-152976NB-I00, PREP2023-001818]. Funding for open access charge: Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

MORE interpretable multi-omic regulatory networks to characterise phenotypes

  • Aguerralde-Martin, Maider|||0000-0001-9266-8689
  • Tarazona, Sonia|||0000-0001-5346-1407
  • Clemente-Císcar, Mónica
  • Conesa, Ana
[EN] Studying phenotype-specific regulatory mechanisms is crucial to understanding the molecular basis of diseases and other complex traits. However, existing approaches for constructing multi-omic regulatory networks MO-RN are scarce, and most cannot integrate diverse omics modalities, incorporate prior biological knowledge, or infer phenotype-specific networks. To address these challenges, we present MORE (Multi-Omics REgulation), a novel R package for inferring multi-modal regulatory networks. MORE is available at https://github.com/BiostatOmics/MORE and supports any number and type of omics layers while optionally incorporating prior regulatory knowledge. Leveraging advanced regression-based models and variable selection techniques, MORE identifies significant regulatory relationships. This tool also provides useful functionalities for the biological interpretation of MO-RN: network visualisations, differential regulatory networks, and functional enrichment analyses of key network features. We evaluated MORE on simulated multi-omic datasets and benchmarked it against state-of-the-art tools. Our tool consistently outperformed other methods regarding accuracy in identifying significant regulators, model goodness-of-fit, and computational efficiency. We further applied MORE to a multi-omic ovarian cancer dataset to uncover tumour subtype-specific regulatory mechanisms associated with distinct survival outcomes. This analysis revealed differential regulatory patterns to understand the molecular basis of each subtype. By addressing the limitations of methods for multi-omic network inference, MORE represents a valuable resource for studying regulatory systems. Its ability to construct phenotype-specific regulatory networks with high accuracy and interpretability positions it as a useful resource for researchers seeking to unravel the complexities of molecular interactions and regulatory mechanisms across diverse biological contexts., This work was supported by the Scientific Foundation of the Spanish Association Against Cancer through the project PERME224336TARA and by Instituto de Salud Carlos III through the project AC22/00058 (co-funded by the European Union as part of the Next Generation EU programme and the Recovery and Resilience Mechanism, MRR), both projects under the frame of ERA PerMed (ERAPERMED2022-141-OVA-PDM). This work also received Funding from the FP7 STATegra project (agreement no. 306000), the Spanish MINECO (BIO2012-40244), and the Spanish MICIN (PID2020-119537RB-100).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Coxmos: interpretable survival models for high-dimensional and multi-omic data

  • Salguero, Pedro
  • Buendía-Galera, Anabel
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] Background Survival analysis in high-dimensional (HD) and multi-block (MB) settings, such as omic and multi-omic studies, poses major methodological challenges due to multicollinearity, low events-per-variable ratios, and limited model interpretability. While Cox Proportional Hazards models remain widely used, their applicability is restricted in HD scenarios. Machine learning approaches can handle such complexity but often lack interpretability. Survival models based on Partial Least Squares (PLS) offer an attractive compromise, yet existing implementations provide limited support for model optimization, evaluation, and interpretation.Results To overcome these limitations, we introduce Coxmos, a CRAN R package that integrates adapted Cox regression models with HD-adapted variable selection, and optimized PLS-based approaches tailored for HD and MB data. Coxmos also provides validation, comparison, interpretation, and visualization tools. Benchmarking on a diverse set of clinical, single-omic, and multi-omic cancer datasets - including breast (BRCA), head and neck (HNSC), and ovarian (HGSOC) cancer - demonstrated that Coxmos outperformed other state-of-the-art machine learning methods, while enhancing interpretability. We illustrated the package's functionalities through two case studies (HGSOC and HNSC), showing how Coxmos facilitates model selection, validation, and biological interpretation in a complex HD and MB survival analysis.Conclusions Coxmos provides a robust, flexible, and interpretable solution for survival analysis in HD and MB data. By combining optimized PLS-based methodologies with rigorous evaluation and rich visualization tools, Coxmos enables reliable survival prediction and facilitates the identification of relevant risk and protective factors in complex biomedical studies. The package fills an important methodological gap and represents a valuable resource for reproducible and interpretable survival modeling in the big data scenario., This work was supported by the Scientific Foundation of the Spanish Association Against Cancer through the project PERME224336TARA and by Instituto de Salud Carlos III through the project AC22/00058 (co-funded by the European Union as part of the Next Generation EU programme and the Recovery and Resilience Mechanism, MRR), both projects under the frame of ERA PerMed (ERAPERMED2022-141 - OVA-PDM). This work was also funded by Generalitat Valenciana (ACIF/2019/081), Spanish MICIN (PID2020-119537RB-100), and Spanish MICIU (PID2023-152976NB-I00).
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez-Jurado, D.
  • Fernández-Vega, A.
  • Del Río, C.
  • Penalba, A.
  • Llucià-Carol, L.
  • Muiño-Acuña, E.
  • Ezcurra-Díaz, G.
  • Guasch-Jiménez, M.
  • Cullell, N.
  • Serrano-Heras, G.
  • Arias-Salazar, L.
  • Vives-Bauza, C.
  • Tur, S.
  • Urra, X.
  • Castellanos, M.
  • Krupinski, J.
  • Freijo-Guerrero, M.
  • Jiménez-Conde, J.
  • Fernández-Pérez, I.
  • Segura, T.
  • Marti-Fabregas, J.
  • Férnandez-Cadenas, I.
  • Montaner, J.
[eng] Background: Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase. Methods: In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein-protein interaction (PPI) analyses. Results: Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs. Conclusion: This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez-Jurado, David
  • Fernández-Vega, Alejandro
  • del Río, Carmen
  • Penalba, Anna
  • Llucià-Carol, Laia
  • Muiño-Acuña, Elena
  • Ezcurra-Díaz, Garbiñe
  • Guasch, Marina
  • Cullel, Natalia
  • Serrano-Heras, Gemma
  • Arias-Salazar, Lourdes
  • Vives-Bauza, Cristófol
  • Tur, Silvia
  • Urra, Xabier
  • Castellanos, María del Mar
  • Krupinski, Jerzy
  • Freijo Guerrero, María del Mar
  • Jiménez-Conde, Jordi
  • Fernández-Pérez, Isabel
  • Segura, Tomás
  • Martí-Fàbregas, Joan
  • Fernández-Cadenas, Israel
  • Montaner, Joan
[Abstract] Background: Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase. Methods: In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein-protein interaction (PPI) analyses. Results: Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs. Conclusion: This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable., This work was funded by the National Institute of Health Carlos III (ISCIII) under the framework of Health Research Projects (PMP21/00165, PREVICTUS; and PI21/01158, ETNIAS) and co-funded by the European Union. D.N-J. was supported by a Río Hortega contract (CM23/00216) from the ISCIII. C.R. was supported by the applied research and innovation project POLIFENEV, co-funded by the European Union – Ministry of Finance and Civil Service – European Funds – Regional Government of Andalusia – Ministry of University, Research and Innovation.A.F-V. was supported by a contract funded through the CRESCENDO project (grant AC22/00005) from the ISCIII. This work was supported by project RD21/0006/0015 and RD24/0009/0007, funded by the ISCIII with public funding from the Cooperative Research Networks for Health Results (RICORS) RICORS-ICTUS.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Localized doxycycline delivery via polymeric nanoparticles anchored to electrospun PCL microfiber patch for MMP-2 inhibition in abdominal aortic aneurysm

  • Bofill Bonet, Carles
  • Febas, Germán
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà Palasí, Noemí
  • Martorell, Jordi
  • Borrós, Salvador
  • Fornaguera, Cristina
Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Quantitative and qualitative comparison of mRNA loading techniques into extracellular vesicles

  • Guarro, Monica
  • van Veen, Stijn
  • Borrós, Salvador
  • Albertazzi, Lorenzo
  • Lecina, Martí
  • Fornaguera, Cristina
Extracellular vesicles (EVs) are increasingly recognized as natural therapeutic delivery systems (DDS). A critical challenge in realizing this potential is the loading of nucleic acids, particularly mRNA, a high molecular weight and very sensitive biomolecule, for which the loading efficiency into EVs is often low. Despite the growing interest in EV-based delivery platforms, relatively few studies have reported efficient loading techniques, and inconsistent or misleading information in the literature hinders progress towards the development of reliable loading of mRNA into EV-based systems. Addressing this gap systematically and quantitatively is crucial for the clinical translation of EVs as DDS. In this study, we compared five different exogenous mRNA loading methods (incubation, sonication, freeze-thaw, electroporation and extrusion) and evaluated their loading efficiencies, as well as their biophysical, biochemical, and functional properties. Here, using direct stochastic optical reconstruction microscopy (dSTORM), as an efficient and reliable characterization approach to assess mRNA loading efficiency into EVs we visualized single EVs and single mRNA molecules and to estimate the percentage of loaded EVs as well as the amount of mRNA molecules loaded per EV. Interestingly, all five strategies demonstrated a high yield of EVs associated with mRNA, with up to 70 % of EVs successfully containing or in contact with mRNA, with minimal disruption to the intrinsic properties of EVs. Although some discrepancies between loading efficiencies, functionality and amount of mRNA molecules per EV, freeze-thaw proved to be the most effective in terms of loading efficiency and amount of mRNA associated molecules per EV. Overall, mRNA incorporation using these exogenous methods remained inefficient and presented significant challenges for large-scale implementation due to substantial mRNA loss. Despite this limitation, the high proportion of successfully loaded or mRNA associated EVs, particularly with freeze-thaw and electroporation, provides, for the first time, a promising foundation for the advancing of mRNA loading on EV-based therapeutic applications., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

PExM: polyplex expansion microscopy for cell trafficking studies

  • Navalón López, María
  • Castells Colldeforns, Pau
  • Pujals, Sílvia
  • Fornaguera, Cristina
  • Borrós, Salvador
Nanomedicine is a field at the intersection of nanotechnology and medicine, promising due to its potential to revolutionize healthcare. Despite its long trajectory, there is still a long road ahead for its full development, and smart design of nanomedicines is still a challenge. Among other problems, this is due to the scarcity of tools available for the precise visualization and comprehension of nano–bio interactions, impeding progress towards the clinical phase. One of the developed tools that stands out to be a strong nanoscopy technique for studying nano-delivery systems within cellular environments is expansion microscopy (ExM). This technique was used for tissue and cell expansion and most recently for lipid molecule expansion inside cells. Herein, we present for the first time polyplex expansion microscopy (PExM); a comprehensive examination of ExM as an already developed technique, but adapted for expanding polymer based nanocarriers, in particular polyplexes within cells, allowing the analysis of their trafficking. With our method set up, PExM will be extensively used for the study of polyplex nanoparticle cell trafficking, becoming a high-resolution technique which can also be applied to primary amine containing polymeric nanoparticles without requiring expensive super-resolution microscopes., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Safety of nanoparticle therapies during pregnancy: A systematic review and meta-analysis

  • Gil Vives, Maria
  • Hernández Hernández, Marta
  • Hernáez, Álvaro
  • Borrós, Salvador
  • Fornaguera Puigvert, Cristina
The exclusion of pregnant women from clinical trials has led to insufficient safety data for many treatments, making it necessary to evaluate their potential benefits and risks during preclinical stages. Nanomedicines show potential for reduced toxicity but there is limited evidence about their safety for pregnant women and their fetuses. We conducted the first systematic review and meta-analysis of the effect of nanoparticles (NPs) on a key outcome of fetal toxicity (low birth weight) in murine models. In the meta-analysis of mouse models, negatively charged NPs tended to decrease birth weight (−69.8 mg, 95 % CI: −196 to 56.5), as did small (−191 mg, 95 % CI: −369 to −13.3) and plain inorganic nanosystems (−249 mg, 95 % CI: −535 to 37.4). In contrast, positively charged NPs resulted in increased birth weight (+29.3 mg, 95 % CI: 23.4 to 35.2). All findings were validated in studies with low heterogeneity and low risk of publication bias. Neither large NPs (+4.37 mg; 95 % CI: −45.3 to 54.0) nor polymer-coated NPs (+16.5 mg; 95 % CI: −44.7 to 77.6) had any clear association with birth weight. Similar results were observed in other models and experimental designs from articles not included in the meta-analysis, although no conclusions were drawn for other parameters due to high variability. Our findings pave the way for future research and the rational development of safer nanomedicines for use during pregnancy., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Stealth mRNA nanovaccines to control lymph node trafficking

  • García-Fernández, Coral
  • Virgilio, Tommaso
  • Latino, Irene
  • Guerra-Rebollo, Marta
  • F. Gonzalez, Santiago
  • Borrós, Salvador
  • Fornaguera, Cristina
mRNA-based vaccines symbolize a new paradigm shift in personalized medicine for the treatment of infectious and non-infectious diseases. However, the reactogenicity associated with the currently approved formulations limits their applicability in autoinflammatory disorders, such as tumour therapeutics. In this study, we present a delivery system showing controlled immunogenicity and minimal non-specific inflammation, allowing for selective delivery of mRNA to antigen presenting cells (APCs) within the medullary region of the lymph nodes. Our platform offers precise control over the trafficking of nanoparticles within the lymph nodes by optimizing stealth and targeting properties, as well as the subsequent opsonization process. By targeting specific cells, we observed a potent adaptive and humoral immune response, which holds promise for preventive and therapeutic anti-tumoral vaccines. Through spatial programming of nanoparticle distribution, we can promote robust immunization, thus improving and expanding the utilization of mRNA vaccines. This innovative approach signifies a remarkable step forward in the field of targeted nanomedicine., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

A dual QTOF–QTrap analytical platform for comprehensive tracking of doxycycline and its degradation byproducts in biological and nanoparticle-based delivery systems

  • Bofill Bonet, Carles
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà, Noemí
  • Martorell, Jordi
  • Fornaguera, Cristina
  • Borrós, Salvador
Doxycycline (DOX) is a second-generation tetracycline antibiotic extensively used in clinical practice, not only for its antimicrobial activity but also for its emerging therapeutic potential in modulating extracellular matrix (ECM) in remodeling processes. Increasing evidence supports its role in attenuating pathological conditions associated with ECM degradation by targeting matrix metalloproteinases type 2 (MMP-2), including cancer progression and abdominal aortic aneurysm (AAA). However, DOX exhibits limited stability in aqueous and semi-physiological environments, undergoing hydrolysis and oxidative reactions that lead to the generation of multiple degradation byproducts, thereby compromising its efficacy and safety profile. In this study, we systematically mapped the degradation pathways of DOX under rigorously controlled physicochemical and biological conditions. High-resolution QTOF mass spectrometry operating in SWATH data-independent acquisition mode enabled unbiased identification of multiple, structurally distinct degradation byproducts, as well as the DOX parent compound, using curated metabolite libraries from SCIEX platform. Building on this annotation step, we established a complementary QTrap-based targeted workflow to quantify low-abundance metabolites intra- and extracellular through isotope-specific transitions derived from the QTOF analysis and to monitor their temporal kinetics with high sensitivity. Together, this integrated analytical strategy provides refined insight into the intrinsic instability of DOX and its potential biological consequences. To translate degradation mapping into a biologically relevant context, OM-PLGA NPs were incorporated as a controlled delivery platform that modulates DOX exposure, slows spontaneous degradation, and creates the matrix conditions required to validate the sensitivity of the QTRAP workflow in complex cellular environments. This validation demonstrated that OM-PLGA nanoparticles not only preserve DOX in its bioactive form through microenvironmental shielding, but also results in enhanced pharmacological activity, particularly sustained inhibition of MMP-2, a central enzyme in AAA-associated ECM remodeling. Together, these results highlight the dual value of the advanced analytical workflow and the nanocarrier strategy, demonstrating how integrating high-resolution mass spectrometry with nanoparticle engineering overcomes the intrinsic instability of DOX and provides deeper mechanistic insight across both analytical and biological dimensions., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization

  • Losada Baranera, Mar
  • GOTOR, GEMMA
  • Borrós, Salvador
  • Fornaguera, Cristina
Messenger RNA (mRNA) has emerged as a transformative modality for modern therapeutics, including vaccines and gene therapies. Ensuring the quality, safety, and efficacy of mRNA products requires the evaluation of critical quality attributes (CQAs) such as sequence integrity, nucleotide modifications, purity, and structural stability. The growing complexity of modified mRNA therapeutics highlights the need for robust and orthogonal analytical strategies. This review summarizes liquid chromatography (LC)-based workflows tailored for mRNA characterization including UV detection and mass spectrometry (MS) strategies. These include nucleoside-level analysis to identify chemical modifications and impurities, partial digestion with oligonucleotide mapping to assess sequence coverage and localization of modifications, and intact mRNA analysis to evaluate global structural integrity and encapsulation efficiency. Case studies illustrate practical applications by directly linking analytical workflows to specific CQAs and regulatory-relevant attributes. By leveraging advances in chromatography and mass spectrometry—including bioinert stationary phases, high-resolution detection, and ion-pairing strategies—these studies enable robust analysis of highly polar, charged, and high-molecular-weight mRNA species. The integration of complementary chromatographic and MS-based workflows supports comprehensive characterization, facilitates regulatory compliance, and informs process and formulation development, ultimately providing a coherent framework for quality control in emerging mRNA therapeutics., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Regulation of mitochondrial apoptosis via siRNA-loaded metallo-alginate hydrogels: A localized and synergistic antitumor therapy

  • Fernandez Alarcon, Jennifer
  • Artigues Cladera, Margalida
  • Rodriguez Camenforte, Natalia
  • Sitia, Giovanni
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Preventing relapse after resection of a primary tumor continues to be an unmet clinical need. Development of adjuvant biomaterials with the capacity to kill residual cancer cells after tumor resection is of clinical importance. Here we developed a library of metallo-alginate hydrogels containing high concentrations of metallic ions such as Ca2+ in combination with Zn2+, Li+, or Mg2+ to disrupt Ca2+ homeostasis in the mitochondria of cancer cells by local hyperthermia. To synergistically kill tumor cells and suppress the growth of rechallenged tumors, we embedded oncogene-silencing nucleic acids (mTOR siRNA) loaded into polymerc nanoparticles (NPs) composed of poly (β-amino esters) in the metallo-alginate hydrogels, targeting cancer cells that activate multi-drug resistance pathways such PI3K/AKT/mTOR. Metabolomic studies showed alterations in the Warburg effect, mitochondrial transport, and the TCA cycle, confirming cancer cell damage. In vivo studies of this targeted therapy in mice demonstrated a sex-dependent effect. Male B16F10-tumor-bearing mice treated with the synergistic therapy showed restrained tumor growth. In contrast, no therapeutic effect was observed in female counterparts. Our results demonstrate that in situ-formed NP-loaded metallo-alginate hydrogels can modulate two distinct immune signaling networks that are relevant for enhancing cancer cell death. On the basis of our findings, this combination therapy emerges as a promising sex-dependent strategy for clinical translation., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics, the good, the bad, and the future

  • Magana Rodriguez, Jose Rodrigo
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Immunotherapy has emerged as a promising approach to cancer treatment, offering improved survival rates and enhanced patients’ quality of life. However, realizing the full potential of immunotherapy in clinical practice remains a challenge, as there is still plenty of room for modulating the complexity of the human immune system in favor of an antitumor immunogenicity. Nanotechnology, with its unique properties, holds promise in augmenting the efficacy of cancer immunotherapies in biotherapeutic protection and site- and time-controlled delivery of the immune modulator biologicals. Polymeric nanoparticles are promising biomaterials among different nanocarriers thanks to their robustness, versatility, and cost-efficient design and production. This perspective paper overviews critical concepts in nanometric advanced delivery systems applied to cancer immunotherapy. We focus on a detailed exploration of the current state of the art and trends in using poly(beta-aminoester) (pBAE) polymers for nucleic acid-based antitumor immunotherapies. Through different examples of the use of pBAE polymers reported in the literature, we revise the main advantages these polymers offer and some challenges to overcome. Finally, the paper provides insights and predictions on the path toward the clinical implementation of cancer nano-immunotherapies, highlighting the potential of pBAE polymers for advancements in this field., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Unveiling the contribution of histidine-end-terminal pBAEs to endosomal escape using super-resCLEM imaging

  • Navalón López, María
  • Andrian, Teodora
  • Albertazzi, Lorenzo
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Pujals, Sílvia
The success of gene therapy focuses on the development of efficient and safe carriers capable of overcoming cellular barriers to deliver genetic material to the nucleus. Poly(beta-amino ester) nanoparticles (pβAE NPs) are promising cationic polymers that can complex nucleic acids to form polyplexes, facilitating intracellular delivery. Among the key intracellular hurdles, endosomal escape remains one of the most critical and debated steps. While the incorporation of histidine into polyplex formulations has been proposed to enhance endosomal escape via proton buffering, definitive evidence of this process has remained elusive. To address this gap, a super-resolution correlative light and electron microscopy (CLEM) approach was employed to decipher the intracellular trafficking of pβAE NPs. Specifically, we compared two pβAE formulations, one incorporating a histidine-arginine end-capping structure (RH) and a control containing only arginine end-capping (R). Our findings revealed that RH polyplexes efficiently escaped endosomes at early timepoints and achieved cytosolic localization, whereas R polyplexes predominantly remained trapped within endo-lysosomal compartments, ultimately undergoing exocytosis or degradation, as confirmed by lysosome-specific staining. This study provides, for the first time, direct high-resolution evidence of histidine-mediated endosomal escape in gene therapy, underscoring the role of histidine in overcoming intracellular barriers. Moreover, it highlights the power of super-resolution correlative imaging techniques in elucidating the nanoscale trafficking of gene delivery systems, enabling more rational design of next generation nanocarriers., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization

  • Losada Baranera, Mar
  • GOTOR, GEMMA
  • Borrós, Salvador
  • Fornaguera, Cristina
Messenger RNA (mRNA) has emerged as a transformative modality for modern therapeutics, including vaccines and gene therapies. Ensuring the quality, safety, and efficacy of mRNA products requires the evaluation of critical quality attributes (CQAs) such as sequence integrity, nucleotide modifications, purity, and structural stability. The growing complexity of modified mRNA therapeutics highlights the need for robust and orthogonal analytical strategies. This review summarizes liquid chromatography (LC)-based workflows tailored for mRNA characterization including UV detection and mass spectrometry (MS) strategies. These include nucleoside-level analysis to identify chemical modifications and impurities, partial digestion with oligonucleotide mapping to assess sequence coverage and localization of modifications, and intact mRNA analysis to evaluate global structural integrity and encapsulation efficiency. Case studies illustrate practical applications by directly linking analytical workflows to specific CQAs and regulatory-relevant attributes. By leveraging advances in chromatography and mass spectrometry—including bioinert stationary phases, high-resolution detection, and ion-pairing strategies—these studies enable robust analysis of highly polar, charged, and high-molecular-weight mRNA species. The integration of complementary chromatographic and MS-based workflows supports comprehensive characterization, facilitates regulatory compliance, and informs process and formulation development, ultimately providing a coherent framework for quality control in emerging mRNA therapeutics., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Regulation of mitochondrial apoptosis via siRNA-loaded metallo-alginate hydrogels: A localized and synergistic antitumor therapy

  • Fernandez Alarcon, Jennifer
  • Artigues Cladera, Margalida
  • Rodriguez Camenforte, Natalia
  • Sitia, Giovanni
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Preventing relapse after resection of a primary tumor continues to be an unmet clinical need. Development of adjuvant biomaterials with the capacity to kill residual cancer cells after tumor resection is of clinical importance. Here we developed a library of metallo-alginate hydrogels containing high concentrations of metallic ions such as Ca2+ in combination with Zn2+, Li+, or Mg2+ to disrupt Ca2+ homeostasis in the mitochondria of cancer cells by local hyperthermia. To synergistically kill tumor cells and suppress the growth of rechallenged tumors, we embedded oncogene-silencing nucleic acids (mTOR siRNA) loaded into polymerc nanoparticles (NPs) composed of poly (β-amino esters) in the metallo-alginate hydrogels, targeting cancer cells that activate multi-drug resistance pathways such PI3K/AKT/mTOR. Metabolomic studies showed alterations in the Warburg effect, mitochondrial transport, and the TCA cycle, confirming cancer cell damage. In vivo studies of this targeted therapy in mice demonstrated a sex-dependent effect. Male B16F10-tumor-bearing mice treated with the synergistic therapy showed restrained tumor growth. In contrast, no therapeutic effect was observed in female counterparts. Our results demonstrate that in situ-formed NP-loaded metallo-alginate hydrogels can modulate two distinct immune signaling networks that are relevant for enhancing cancer cell death. On the basis of our findings, this combination therapy emerges as a promising sex-dependent strategy for clinical translation., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics, the good, the bad, and the future

  • Magana Rodriguez, Jose Rodrigo
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Immunotherapy has emerged as a promising approach to cancer treatment, offering improved survival rates and enhanced patients’ quality of life. However, realizing the full potential of immunotherapy in clinical practice remains a challenge, as there is still plenty of room for modulating the complexity of the human immune system in favor of an antitumor immunogenicity. Nanotechnology, with its unique properties, holds promise in augmenting the efficacy of cancer immunotherapies in biotherapeutic protection and site- and time-controlled delivery of the immune modulator biologicals. Polymeric nanoparticles are promising biomaterials among different nanocarriers thanks to their robustness, versatility, and cost-efficient design and production. This perspective paper overviews critical concepts in nanometric advanced delivery systems applied to cancer immunotherapy. We focus on a detailed exploration of the current state of the art and trends in using poly(beta-aminoester) (pBAE) polymers for nucleic acid-based antitumor immunotherapies. Through different examples of the use of pBAE polymers reported in the literature, we revise the main advantages these polymers offer and some challenges to overcome. Finally, the paper provides insights and predictions on the path toward the clinical implementation of cancer nano-immunotherapies, highlighting the potential of pBAE polymers for advancements in this field., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Safety of nanoparticle therapies during pregnancy: A systematic review and meta-analysis

  • Gil Vives, Maria
  • Hernández Hernández, Marta
  • Hernáez, Álvaro
  • Borrós, Salvador
  • Fornaguera Puigvert, Cristina
The exclusion of pregnant women from clinical trials has led to insufficient safety data for many treatments, making it necessary to evaluate their potential benefits and risks during preclinical stages. Nanomedicines show potential for reduced toxicity but there is limited evidence about their safety for pregnant women and their fetuses. We conducted the first systematic review and meta-analysis of the effect of nanoparticles (NPs) on a key outcome of fetal toxicity (low birth weight) in murine models. In the meta-analysis of mouse models, negatively charged NPs tended to decrease birth weight (−69.8 mg, 95 % CI: −196 to 56.5), as did small (−191 mg, 95 % CI: −369 to −13.3) and plain inorganic nanosystems (−249 mg, 95 % CI: −535 to 37.4). In contrast, positively charged NPs resulted in increased birth weight (+29.3 mg, 95 % CI: 23.4 to 35.2). All findings were validated in studies with low heterogeneity and low risk of publication bias. Neither large NPs (+4.37 mg; 95 % CI: −45.3 to 54.0) nor polymer-coated NPs (+16.5 mg; 95 % CI: −44.7 to 77.6) had any clear association with birth weight. Similar results were observed in other models and experimental designs from articles not included in the meta-analysis, although no conclusions were drawn for other parameters due to high variability. Our findings pave the way for future research and the rational development of safer nanomedicines for use during pregnancy., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prediabetes and CKD: Does a causal relationship exist, Prediabetes y ERC: ¿existe una relación causal?

  • Rico-Fontalvo, Jorge
  • daza arnedo, rodrigo andres
  • Navarro-Blackaller, Guillermo
  • Medina-Gonzalez, Ramon
  • Rodriguez Yanez, Tomas
  • Soler, María José
Prediabetes; Chronic kidney disease; Albuminuria, Prediabetes; Enfermedad renal crónica; Albuminuria, Prediabetis; Malaltia renal crònica; Albuminuria, The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes (preDM) and the development of CKD., La relación entre diabetes y el desarrollo de complicaciones renales es bien conocida; sin embargo la asociación entre prediabetes y la resistencia a la insulina con el daño en la función renal apenas ha sido evaluada. Varios factores podrían explicar este fenómeno, desde la falta de estandarización en las definiciones de prediabetes, hasta la errática e inconsistente evidencia en estudios epidemiológicos y de cohortes a gran escala. Parece que las vías fisiopatológicas en la prediabetes podrían estar relacionadas con inflamación y la hiperactivación del sistema neuro-hormonal, factores presentes incluso antes de la aparición de la diabetes, que podrían ser los principales impulsores de la hiperfiltración glomerular, albuminuria y alteración de la tasa de filtración glomerular. Es posible que los tratamientos existentes para el control de la diabetes, como metformina o los inhibidores SGLT2 también pueden ser útiles en pacientes con prediabetes con evidencia de daño renal funcional o estructural. El propósito de esta revisión es resumir la evidencia sobre la relación entre la prediabetes (preDM) y el desarrollo de la ERC., M.J.S. is funded by ISCIIII-FEDER and ISCIII, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Stealth mRNA nanovaccines to control lymph node trafficking

  • García-Fernández, Coral
  • Virgilio, Tommaso
  • Latino, Irene
  • Guerra-Rebollo, Marta
  • F. Gonzalez, Santiago
  • Borrós, Salvador
  • Fornaguera, Cristina
mRNA-based vaccines symbolize a new paradigm shift in personalized medicine for the treatment of infectious and non-infectious diseases. However, the reactogenicity associated with the currently approved formulations limits their applicability in autoinflammatory disorders, such as tumour therapeutics. In this study, we present a delivery system showing controlled immunogenicity and minimal non-specific inflammation, allowing for selective delivery of mRNA to antigen presenting cells (APCs) within the medullary region of the lymph nodes. Our platform offers precise control over the trafficking of nanoparticles within the lymph nodes by optimizing stealth and targeting properties, as well as the subsequent opsonization process. By targeting specific cells, we observed a potent adaptive and humoral immune response, which holds promise for preventive and therapeutic anti-tumoral vaccines. Through spatial programming of nanoparticle distribution, we can promote robust immunization, thus improving and expanding the utilization of mRNA vaccines. This innovative approach signifies a remarkable step forward in the field of targeted nanomedicine., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PExM: polyplex expansion microscopy for cell trafficking studies

  • Navalón López, María
  • Castells Colldeforns, Pau
  • Pujals, Sílvia
  • Fornaguera, Cristina
  • Borrós, Salvador
Nanomedicine is a field at the intersection of nanotechnology and medicine, promising due to its potential to revolutionize healthcare. Despite its long trajectory, there is still a long road ahead for its full development, and smart design of nanomedicines is still a challenge. Among other problems, this is due to the scarcity of tools available for the precise visualization and comprehension of nano–bio interactions, impeding progress towards the clinical phase. One of the developed tools that stands out to be a strong nanoscopy technique for studying nano-delivery systems within cellular environments is expansion microscopy (ExM). This technique was used for tissue and cell expansion and most recently for lipid molecule expansion inside cells. Herein, we present for the first time polyplex expansion microscopy (PExM); a comprehensive examination of ExM as an already developed technique, but adapted for expanding polymer based nanocarriers, in particular polyplexes within cells, allowing the analysis of their trafficking. With our method set up, PExM will be extensively used for the study of polyplex nanoparticle cell trafficking, becoming a high-resolution technique which can also be applied to primary amine containing polymeric nanoparticles without requiring expensive super-resolution microscopes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A dual QTOF–QTrap analytical platform for comprehensive tracking of doxycycline and its degradation byproducts in biological and nanoparticle-based delivery systems

  • Bofill Bonet, Carles
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà, Noemí
  • Martorell, Jordi
  • Fornaguera, Cristina
  • Borrós, Salvador
Doxycycline (DOX) is a second-generation tetracycline antibiotic extensively used in clinical practice, not only for its antimicrobial activity but also for its emerging therapeutic potential in modulating extracellular matrix (ECM) in remodeling processes. Increasing evidence supports its role in attenuating pathological conditions associated with ECM degradation by targeting matrix metalloproteinases type 2 (MMP-2), including cancer progression and abdominal aortic aneurysm (AAA). However, DOX exhibits limited stability in aqueous and semi-physiological environments, undergoing hydrolysis and oxidative reactions that lead to the generation of multiple degradation byproducts, thereby compromising its efficacy and safety profile. In this study, we systematically mapped the degradation pathways of DOX under rigorously controlled physicochemical and biological conditions. High-resolution QTOF mass spectrometry operating in SWATH data-independent acquisition mode enabled unbiased identification of multiple, structurally distinct degradation byproducts, as well as the DOX parent compound, using curated metabolite libraries from SCIEX platform. Building on this annotation step, we established a complementary QTrap-based targeted workflow to quantify low-abundance metabolites intra- and extracellular through isotope-specific transitions derived from the QTOF analysis and to monitor their temporal kinetics with high sensitivity. Together, this integrated analytical strategy provides refined insight into the intrinsic instability of DOX and its potential biological consequences. To translate degradation mapping into a biologically relevant context, OM-PLGA NPs were incorporated as a controlled delivery platform that modulates DOX exposure, slows spontaneous degradation, and creates the matrix conditions required to validate the sensitivity of the QTRAP workflow in complex cellular environments. This validation demonstrated that OM-PLGA nanoparticles not only preserve DOX in its bioactive form through microenvironmental shielding, but also results in enhanced pharmacological activity, particularly sustained inhibition of MMP-2, a central enzyme in AAA-associated ECM remodeling. Together, these results highlight the dual value of the advanced analytical workflow and the nanocarrier strategy, demonstrating how integrating high-resolution mass spectrometry with nanoparticle engineering overcomes the intrinsic instability of DOX and provides deeper mechanistic insight across both analytical and biological dimensions., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Localized doxycycline delivery via polymeric nanoparticles anchored to electrospun PCL microfiber patch for MMP-2 inhibition in abdominal aortic aneurysm

  • Bofill Bonet, Carles
  • Febas, Germán
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà Palasí, Noemí
  • Martorell, Jordi
  • Borrós, Salvador
  • Fornaguera, Cristina
Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quantitative and qualitative comparison of mRNA loading techniques into extracellular vesicles

  • Guarro, Monica
  • van Veen, Stijn
  • Borrós, Salvador
  • Albertazzi, Lorenzo
  • Lecina, Martí
  • Fornaguera, Cristina
Extracellular vesicles (EVs) are increasingly recognized as natural therapeutic delivery systems (DDS). A critical challenge in realizing this potential is the loading of nucleic acids, particularly mRNA, a high molecular weight and very sensitive biomolecule, for which the loading efficiency into EVs is often low. Despite the growing interest in EV-based delivery platforms, relatively few studies have reported efficient loading techniques, and inconsistent or misleading information in the literature hinders progress towards the development of reliable loading of mRNA into EV-based systems. Addressing this gap systematically and quantitatively is crucial for the clinical translation of EVs as DDS. In this study, we compared five different exogenous mRNA loading methods (incubation, sonication, freeze-thaw, electroporation and extrusion) and evaluated their loading efficiencies, as well as their biophysical, biochemical, and functional properties. Here, using direct stochastic optical reconstruction microscopy (dSTORM), as an efficient and reliable characterization approach to assess mRNA loading efficiency into EVs we visualized single EVs and single mRNA molecules and to estimate the percentage of loaded EVs as well as the amount of mRNA molecules loaded per EV. Interestingly, all five strategies demonstrated a high yield of EVs associated with mRNA, with up to 70 % of EVs successfully containing or in contact with mRNA, with minimal disruption to the intrinsic properties of EVs. Although some discrepancies between loading efficiencies, functionality and amount of mRNA molecules per EV, freeze-thaw proved to be the most effective in terms of loading efficiency and amount of mRNA associated molecules per EV. Overall, mRNA incorporation using these exogenous methods remained inefficient and presented significant challenges for large-scale implementation due to substantial mRNA loss. Despite this limitation, the high proportion of successfully loaded or mRNA associated EVs, particularly with freeze-thaw and electroporation, provides, for the first time, a promising foundation for the advancing of mRNA loading on EV-based therapeutic applications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unveiling the contribution of histidine-end-terminal pBAEs to endosomal escape using super-resCLEM imaging

  • Navalón López, María
  • Andrian, Teodora
  • Albertazzi, Lorenzo
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Pujals, Sílvia
The success of gene therapy focuses on the development of efficient and safe carriers capable of overcoming cellular barriers to deliver genetic material to the nucleus. Poly(beta-amino ester) nanoparticles (pβAE NPs) are promising cationic polymers that can complex nucleic acids to form polyplexes, facilitating intracellular delivery. Among the key intracellular hurdles, endosomal escape remains one of the most critical and debated steps. While the incorporation of histidine into polyplex formulations has been proposed to enhance endosomal escape via proton buffering, definitive evidence of this process has remained elusive. To address this gap, a super-resolution correlative light and electron microscopy (CLEM) approach was employed to decipher the intracellular trafficking of pβAE NPs. Specifically, we compared two pβAE formulations, one incorporating a histidine-arginine end-capping structure (RH) and a control containing only arginine end-capping (R). Our findings revealed that RH polyplexes efficiently escaped endosomes at early timepoints and achieved cytosolic localization, whereas R polyplexes predominantly remained trapped within endo-lysosomal compartments, ultimately undergoing exocytosis or degradation, as confirmed by lysosome-specific staining. This study provides, for the first time, direct high-resolution evidence of histidine-mediated endosomal escape in gene therapy, underscoring the role of histidine in overcoming intracellular barriers. Moreover, it highlights the power of super-resolution correlative imaging techniques in elucidating the nanoscale trafficking of gene delivery systems, enabling more rational design of next generation nanocarriers., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  • Hurtado-Navarro, Laura|||0000-0002-9544-6042
  • Cuenca-Zamora, Ernesto José
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Such, Esperanza|||0000-0001-6892-403X
  • Soler-Espejo, Eva
  • Martínez-Banaclocha, Helios
  • Hernández Bermúdez, J.
  • Marco-Ayala, Javier
  • Martínez-Alarcón, Laura
  • Linares-Latorre, Lola
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Amat, Paula
  • González, Teresa
  • Arnan, Montserrat
  • Pomares-Marín, Helena
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Chen-Liang, Tzu Hua
  • Herranz, María T.
  • García-Palenciano, Carlos
  • Morales, María Luz
  • Jerez, Andrés|||0000-0002-2079-6638
  • Lozano, María L.
  • Teruel-Montoya, Raúl
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
Chronic myelomonocytic leukemia (CMML) is frequently associated with mutations in the rat sarcoma gene (RAS), leading to worse prognosis. RAS mutations result in active RAS-GTP proteins, favoring myeloid cell proliferation and survival and inducing the NLRP3 inflammasome together with the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which promote caspase-1 activation and interleukin (IL)-1β release. Here, we report, in a cohort of CMML patients with mutations in KRAS, a constitutive activation of the NLRP3 inflammasome in monocytes, evidenced by ASC oligomerization and IL-1β release, as well as a specific inflammatory cytokine signature. Treatment of a CMML patient with a KRAS mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Weber, Ralf J.M.|||0000-0002-8796-4771
  • Lloyd, Gavin R.|||0000-0001-7989-6695
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Jankevics, Andris|||0000-0003-2095-6846
  • Winder, Catherine|||0000-0002-1648-5255
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: In this study, we evaluated the lipidome alterations caused by type 1 diabetes (T1D) and type 2 diabetes (T2D), by determining lipids significantly associated with diabetes overall and in both sexes, and lipids associated with the glycaemic state. Methods: An untargeted lipidomic analysis was performed to measure the lipid profiles of 360 subjects (91 T1D, 91 T2D, 74 with prediabetes and 104 controls (CT)) without cardiovascular and/or chronic kidney disease. Ultra-high performance liquid chromatography-electrospray ionization mass spectrometry (UHPLC-ESI-MS) was conducted in two ion modes (positive and negative). We used multiple linear regression models to (1) assess the association between each lipid feature and each condition, (2) determine sex-specific differences related to diabetes, and (3) identify lipids associated with the glycaemic state by considering the prediabetes stage. The models were adjusted by sex, age, hypertension, dyslipidaemia, body mass index, glucose, smoking, systolic blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, alternate Mediterranean diet score (aMED) and estimated glomerular filtration rate (eGFR); diabetes duration and glycated haemoglobin (HbA1c) were also included in the comparison between T1D and T2D. Results: A total of 54 unique lipid subspecies from 15 unique lipid classes were annotated. Lysophosphatidylcholines (LPC) and ceramides (Cer) showed opposite effects in subjects with T1D and subjects with T2D, LPCs being mainly up-regulated in T1D and down-regulated in T2D, and Cer being up-regulated in T2D and down-regulated in T1D. Also, Phosphatidylcholines were clearly down-regulated in subjects with T1D. Regarding sex-specific differences, ceramides and phosphatidylcholines exhibited important diabetes-associated differences due to sex. Concerning the glycaemic state, we found a gradual increase of a panel of 1-deoxyceramides from normoglycemia to prediabetes to T2D. Conclusions: Our findings revealed an extensive disruption of lipid metabolism in both T1D and T2D. Additionally, we found sex-specific lipidome changes associated with diabetes, and lipids associated with the glycaemic state that can be linked to previously described molecular mechanisms in diabetes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Prediabetes and CKD: Does a causal relationship exist, Prediabetes y ERC: ¿existe una relación causal?

  • Rico-Fontalvo, Jorge
  • daza arnedo, rodrigo andres
  • Navarro-Blackaller, Guillermo
  • Medina-Gonzalez, Ramon
  • Rodriguez Yanez, Tomas
  • Soler, María José
Prediabetes; Chronic kidney disease; Albuminuria, Prediabetes; Enfermedad renal crónica; Albuminuria, Prediabetis; Malaltia renal crònica; Albuminuria, The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes (preDM) and the development of CKD., La relación entre diabetes y el desarrollo de complicaciones renales es bien conocida; sin embargo la asociación entre prediabetes y la resistencia a la insulina con el daño en la función renal apenas ha sido evaluada. Varios factores podrían explicar este fenómeno, desde la falta de estandarización en las definiciones de prediabetes, hasta la errática e inconsistente evidencia en estudios epidemiológicos y de cohortes a gran escala. Parece que las vías fisiopatológicas en la prediabetes podrían estar relacionadas con inflamación y la hiperactivación del sistema neuro-hormonal, factores presentes incluso antes de la aparición de la diabetes, que podrían ser los principales impulsores de la hiperfiltración glomerular, albuminuria y alteración de la tasa de filtración glomerular. Es posible que los tratamientos existentes para el control de la diabetes, como metformina o los inhibidores SGLT2 también pueden ser útiles en pacientes con prediabetes con evidencia de daño renal funcional o estructural. El propósito de esta revisión es resumir la evidencia sobre la relación entre la prediabetes (preDM) y el desarrollo de la ERC., M.J.S. is funded by ISCIIII-FEDER and ISCIII, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).